Division of Nephrology, University Hospital A Coruña, A Coruña, Spain.
Division of Nephrology, University Hospital A Coruña, A Coruña, Spain,
Am J Nephrol. 2020;51(1):54-64. doi: 10.1159/000504870. Epub 2019 Dec 6.
The evidence linking low serum sodium levels with the risk of mortality in peritoneal dialysis (PD) patients is controversial. Considering the different mechanisms contributing to hyponatremia in these patients, it is conceivable that the prognostic significance of this factor may vary, according to the clinical setting.
Following a retrospective, observational design, we analyzed the association between hyponatremia and mortality in 748 patients incident on PD. We applied multivariate strategies of analysis, with the main objective of identifying subgroups of patients in whom hyponatremia could sustain different degrees of association with mortality (main outcome variable). For this purpose, we performed preliminary analyses to: (1) disclose predictors of serum sodium levels before and after (mean of first 3 months) initiation of PD (main study variable) and (2) investigate the overall prognostic significance of hyponatremia, in our patients.
Comorbidity, hypoalbuminemia, and lower glomerular filtration rate (GFR) were main predictors of hyponatremia. Use of icodextrin was another inverse correlate of serum sodium, and the only consistent predictor of a decline of natremia, once PD was started. Multivariate analysis confirmed early hyponatremia as an independent marker of survival. However, stratified analyses showed that this association was most apparent in specific subsets, namely, hypoalbuminemic, more anemic patients with higher baseline levels of GFR and C-reactive protein and faster peritoneal solute transport rates. Other factors potentially reinforcing the prognostic significance of hyponatremia included lower lean body mass levels, nonprescription of renin-angiotensin-aldosterone system antagonists, and use of icodextrin-based PD solution. On the contrary, baseline overhydration or categorization by classic predictors of mortality (age, comorbidity, diabetes) did not appear to influence the risk pattern associated with lower serum sodium levels.
Our results suggest that hyponatremia performs as a consistent correlate of the risk of mortality mainly in PD patients manifesting direct or indirect signs of inflammation and wasting, while this association is not apparently linked to the presence of overhydration or nominal, preexisting comorbid conditions.
低血清钠水平与腹膜透析(PD)患者死亡风险之间的关联存在争议。考虑到导致这些患者低钠血症的不同机制,可以想象,根据临床情况,该因素的预后意义可能有所不同。
我们采用回顾性观察性设计,分析了 748 例新接受 PD 的患者中低钠血症与死亡率之间的关系。我们应用了多变量分析策略,主要目的是确定低钠血症与死亡率之间存在不同程度关联的患者亚组(主要结局变量)。为此,我们进行了初步分析:(1)揭示 PD 开始前和开始后(前 3 个月的平均值)血清钠水平的预测因素(主要研究变量),(2)研究低钠血症在我们患者中的整体预后意义。
合并症、低白蛋白血症和较低的肾小球滤过率(GFR)是低钠血症的主要预测因素。使用艾考糊精也是血清钠的另一个负相关因素,而且是 PD 开始后血清钠下降的唯一一致预测因素。多变量分析证实早期低钠血症是生存的独立标志物。然而,分层分析表明,这种关联在特定亚组中更为明显,即低白蛋白血症、贫血更严重、基线 GFR 和 C 反应蛋白水平更高以及腹膜溶质转运更快的患者。其他可能增强低钠血症预后意义的因素包括较低的瘦体重水平、未开处方使用肾素-血管紧张素-醛固酮系统拮抗剂以及使用艾考糊精为基础的 PD 溶液。相反,基线体液过多或根据死亡率的经典预测因素(年龄、合并症、糖尿病)分类似乎不会影响与低血清钠水平相关的风险模式。
我们的结果表明,低钠血症主要与表现出直接或间接炎症和消耗迹象的 PD 患者的死亡风险相关,而这种关联与体液过多或名义上的、预先存在的合并症无关。